PainTEQ Unveils New SI Joint Clinical Evidence at ASPN
TAMPA, Fla., July 16, 2026 PainTEQ has unveiled new scientific evidence supporting its cortical-piercing posterior sacroiliac (SI) joint fixation...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
TAMPA, Fla., July 16, 2026 PainTEQ has unveiled new scientific evidence supporting its cortical-piercing posterior sacroiliac (SI) joint fixation...
CHENGDU, China, July 15, 2026 Kelun-Biotech and Harbour BioMed have announced that China’s National Medical Products Administration (NMPA) has...
MALVERN, Pa., July 15, 2026 MAXONA Pharmaceuticals has received U.S. FDA Investigational New Drug (IND) clearance to initiate a...
BERKELEY HEIGHTS, N.J., July 13, 2026 Tonix Pharmaceuticals announced a major managed Medicare payer agreement that will expand pharmacy...
DUBLIN, Ireland, July 8, 2026 Keenova Therapeutics plc has announced positive Phase 3 clinical trial results for XIAFLEX® (collagenase...
OSLO, Norway, June 16, 2026 SonoClear AS has announced that findings from its pivotal multicenter study evaluating the SonoClear®...
LOS ANGELES, June 16, 2026 Nervonik Inc., a clinical-stage medical device company focused on next-generation neuromodulation technologies, has announced...
NEW ORLEANS, Louisiana, June 11, 2026 Gan & Lee Pharmaceuticals presented four significant research findings from its innovative metabolic...
MELBOURNE, Australia, June 11, 2026 Scientists have identified Lanthionine Synthetase C-Like Protein 1 (LANCL1) as a promising new therapeutic...
SASKATOON, Saskatchewan, June 11, 2026 ZYUS Life Sciences Corporation announced a strategic corporate realignment designed to sharpen its focus...
